Skip to content
OpenCapital
Get started

Disc Medicine IRON Lease Payments

Lease Payments at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0×0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeasePayments.

The official record: Disc Medicine’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's lease payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's lease payments?
Disc Medicine (IRON) reported lease payments of $212.5K in Q4 2025.
How has Disc Medicine's lease payments changed year-over-year?
Disc Medicine's lease payments increased by 18.4% year-over-year, from $179.5K to $212.5K.
What is the long-term trend for Disc Medicine's lease payments?
Over 2 years (2023 to 2025), Disc Medicine's lease payments has grown at a 113.8% compound annual growth rate (CAGR), from $186K to $850K.
What does lease payments mean?
This represents the actual cash outflows made by the company to satisfy its operating lease obligations during the period. Unlike non-cash lease expenses, this metric reflects the tangible impact of lease commitments on the company's liquidity. It is a critical component for assessing the company's fixed cost structure and ongoing cash burn.